The agency said the first round of pricing talks, which involved drugs like the blood thinners Eliquis and Xarelto, will result in $6 billion in savings for taxpayers.
Read more about this post on BioPharmaDive
Trending
- Singapore and China Expand Drug Oversight to Include Gene Therapies
- Global Non-Animal Testing Market Set to Hit $29.4 Billion by 2030 with 13.5% CAGR
- EU Strengthens Commitment to Global Health Amid US Aid Cuts
- Analysts Update Outlook for Legend Biotech Following Strong Q1 Results
- Opening the Door to Clearer FDA Guidance on Off-Label Communications
- Leading Ladies Shaping the Future of Health
- Boehringer Ingelheim Enhances Immunology Pipeline with New Antibody Licensing Agreement
- Delaware Healthcare Spending Surpasses Expectations
